**Core Concept**
The question is testing the knowledge of long-acting inhalational bronchodilators used in the management of chronic obstructive pulmonary disease (COPD) and asthma. These medications work by relaxing the smooth muscles in the airways, thereby increasing airflow and improving lung function.

**Why the Correct Answer is Right**
The correct answer is a long-acting beta-2 agonist (LABA). LABAs, such as salmeterol and formoterol, have a duration of action of 12 hours or more. They work by stimulating the beta-2 adrenergic receptors in the airway smooth muscles, leading to bronchodilation and improved lung function. This is in contrast to short-acting beta-2 agonists (SABAs), such as albuterol, which have a duration of action of 4-6 hours.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it does not specify a long-acting bronchodilator. Short-acting bronchodilators, such as SABAs, are not suitable for long-term management of COPD and asthma.
**Option B:** This option is incorrect because it is a type of inhalation corticosteroid, which is used to reduce inflammation in the airways but does not have bronchodilatory properties.
**Option C:** This option is incorrect because it is a type of anticholinergic agent, which can be used as a bronchodilator but is not a long-acting option.

**Clinical Pearl / High-Yield Fact**
It's essential to note that LABAs should be used in combination with inhaled corticosteroids (ICS) for the long-term management of COPD and asthma. This combination is known as a "step-up" therapy, where the addition of a LABA is used to enhance bronchodilation and improve lung function.

**Correct Answer:** D.